CEPI Awards $5 Million to Ethris for Innovative RNA Vaccine Development

11 February 2024; OSLO; PLANEGG:

The Coalition for Epidemic Preparedness Innovations (CEPI) has made a significant investment by awarding a $5 million funding grant to Ethris, a leading clinical-stage biotechnology company. Ethris is renowned for its work in developing next-generation RNA therapeutics and vaccines. The funding will support groundbreaking research aimed at creating spray-dried RNA vaccines that can remain stable at room temperature and be delivered via nasal spray. This innovation could revolutionize vaccine distribution and accessibility, potentially ending future disease outbreaks more quickly.

The Promise of Spray-Dried RNA Vaccines

Spray-drying, a method commonly used in asthma treatments such as dry powder inhalers, involves rapidly drying liquids using hot gas to create stable powders suitable for respiratory delivery. Applying this technique to RNA vaccines could overcome several major challenges:

• Eliminating Cold Storage Needs: Current RNA vaccines require ultra-low-temperature storage, which is impractical in many parts of the world.
• Simplifying Delivery: The complexity of existing delivery systems can be daunting, especially in low-resource settings.
• Enhancing Mucosal Immunity: Nasal administration can promote mucosal immunity, potentially reducing viral transmission.

Dr. Raafat Fahim’s Expertise and Vision

Dr. Raafat Fahim, Interim Executive Director of Manufacturing and Supply Chain at CEPI, expressed optimism about this innovative approach:

“Spray drying techniques and nasal delivery medicines are well-established; however, their application to RNA-based vaccines represents an innovative approach. If successful, this method would enhance access to RNA-based vaccines by increasing their thermostability and offering an alternative for individuals with needle phobia. Additionally, it may elicit a more robust immune response and potentially reduce transmission. Collectively, this technology may improve our ability to contain future epidemic or pandemic threats, compared to current RNA vaccines.”

Christian Plank’s Leadership at Ethris

Christian Plank, Chief Technology Officer at Ethris, shared similar enthusiasm:

“Spray-drying for RNA-based vaccines could make them more practical and accessible similar to the established standards in respiratory medicine.”

With CEPI’s support, “we aim to demonstrate the feasibility of spray-drying for RNA formulations, enabling vaccines to remain stable at room temperature while allowing for simpler, needle-free administration. If successful, this approach has the potential to transform vaccine delivery and accessibility on a global scale.”

Project Objectives

The CEPI-funded project will tackle two main objectives:

• Developing a spray-dried mucosal RNA vaccine platform that is stable at room temperature and capable of generating a localized immune response.
• Establishing an automated RNA manufacturing process that simplifies production, reduces costs, and supports rapid, scalable vaccine development.

Benefits and Future Implications

Both advancements aim to address key challenges in RNA vaccine accessibility, particularly in low-resource settings:

• Eliminating Cold-Chain Logistics: Spray-dried vaccines will facilitate distribution to regions lacking the necessary infrastructure.
• Automated Manufacturing Processes: These processes will shorten production timelines, enabling faster responses to outbreaks and reducing costs to ensure affordability.

Should the research prove successful, the technology will adhere to Good Manufacturing Practice (GMP) standards, ensuring high-quality vaccine production. Initial tests will focus on developing a functional spray-dried RNA vaccine candidate with a focus on influenza, a proof-of-concept designed to demonstrate the viability of this approach.

Commitment to Equitable Access

CEPI’s primary mission is to accelerate the development of vaccines that are accessible to all people in need. This funding supports their goal of making advanced medical technologies available globally, including in regions with limited resources.

About CEPI

CEPI is a unique collaboration between public, private, philanthropic, and civil organizations. Their mission is to advance the development of vaccines against emerging infectious diseases, aiming to create vaccines accessible to everyone during an outbreak.

About Ethris

Ethris is dedicated to pioneering innovative biotechnology solutions that can democratize access to cutting-edge therapies. For more information, visit www.ethris.com.

Conclusion

The collaboration between CEPI and Ethris represents a significant step forward in vaccine technology, highlighting the potential of RNA vaccines for global health. By enhancing stability and simplifying delivery, these spray-dried RNA vaccines could play a crucial role in the rapid response to future pandemics and contribute to a healthier global community.

We invite you to share your thoughts on this groundbreaking development in the world of biotechnology and vaccine research. Your feedback can help spark further discussions and insights.

Like, comment, and share this article to spread the word about innovative advancements in vaccine technology.